Sanofi (SNY) Asset Writedowns and Impairment (2009 - 2025)

Sanofi has disclosed Asset Writedowns and Impairment across 17 years of filings, most recently posting -$2.6 billion for Q4 2025.

• Asset Writedowns and Impairment for Q4 2025 came in at -$2.6 billion, down 456.07% year-over-year; the trailing twelve-month figure through Dec 2025 was -$3.1 billion (down 1064.66% YoY), and the FY2025 annual result was -$2.6 billion, down 456.07% from the prior year.
• Asset Writedowns and Impairment came in at -$2.6 billion for Q4 2025 at Sanofi, down from -$266.5 million in the prior quarter.
• In the past five years, Asset Writedowns and Impairment ranged from a high of $1.6 billion in Q3 2022 to a low of -$2.6 billion in Q4 2025.
• The 5-year median for Asset Writedowns and Impairment is -$17.2 million (2021), against an average of -$138.1 million.
• Across the five-year window, Asset Writedowns and Impairment jumped 135500.8% in 2022 and sank 4439.8% in 2024, its largest moves.
• Sanofi's Asset Writedowns and Impairment stood at -$17.2 million in 2021, then surged by 2799.32% to $463.2 million in 2022, then sank by 308.13% to -$964.0 million in 2023, then jumped by 51.34% to -$469.1 million in 2024, then sank by 456.07% to -$2.6 billion in 2025.
• The last three Asset Writedowns and Impairment figures came in at -$2.6 billion (Q4 2025), -$266.5 million (Q3 2025), and -$209.4 million (Q2 2025), per Business Quant data.